Barclays
CLVS

Barclays’s Clovis Oncology, Inc. CLVS Stock Holding History

Barclays’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-182,300
Closed -$875K – 5336
2020
Q4 		$875K Sell
182,300
-16,000
-8% -$80.9K ﹤0.01% 2853
2020
Q3 		$1.16M Sell
198,300
-3,400
-2% -$20.3K ﹤0.01% 2559
2020
Q2 		$1.36M Sell
201,700
-200,600
-50% -$1.52M ﹤0.01% 2475
2020
Q1 		$2.56M Sell
402,300
-297,000
-42% -$2.38M ﹤0.01% 2050
2019
Q4 		$7.29M Buy
699,300
+391,600
+127% +$2.85M ﹤0.01% 1646
2019
Q3 		$1.21M Buy
307,700
+275,200
+847% +$2.23M ﹤0.01% 3477
2019
Q2 		$483K Sell
32,500
-5,700
-15% -$103K ﹤0.01% 4351
2019
Q1 		$948K Sell
38,200
-29,200
-43% -$732K ﹤0.01% 3454
2018
Q4 		$1.21M Sell
67,400
-47,500
-41% -$971K ﹤0.01% 2924
2018
Q3 		$3.38M Sell
114,900
-6,900
-6% -$267K ﹤0.01% 2250
2018
Q2 		$5.54M Buy
121,800
+54,300
+80% +$2.64M ﹤0.01% 1644
2018
Q1 		$3.56M Sell
67,500
-359,900
-84% -$21M ﹤0.01% 1902
2017
Q4 		$29.1M Buy
427,400
+298,500
+232% +$20.9M 0.02% 614
2017
Q3 		$10.6M Sell
128,900
-187,000
-59% -$14.8M 0.01% 1018
2017
Q2 		$29.6M Buy
315,900
+293,600
+1,317% +$18M 0.03% 439
2017
Q1 		$1.42M Buy
22,300
+20,300
+1,015% +$1.23M ﹤0.01% 2407
2016
Q4 		$89K Sell
2,000
-65,400
-97% -$2.3M ﹤0.01% 4830
2016
Q3 		$2.43M Buy
67,400
+23,400
+53% +$502K ﹤0.01% 1838
2016
Q2 		$604K Sell
44,000
-56,000
-56% -$819K ﹤0.01% 3047
2016
Q1 		$1.9M Buy
100,000
+55,700
+126% +$1.18M ﹤0.01% 1964
2015
Q4 		$1.55M Buy
+44,300
New +$2.86M ﹤0.01% 2235

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Barclays's CLVS Position: Q4 2022 in Review

Barclays sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 132,775 shares — an estimated $158K sold.

Barclays first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $13M in Q4 2016. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Barclays reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 132,775 Clovis Oncology, Inc. shares in Q4 2022, an estimated $158K.
  • Barclays first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Barclays's Clovis Oncology, Inc. position peaked at $13M in Q4 2016.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.